Gouty Arthritis (Gout) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Gouty Arthritis (Gout) – Pipeline Review, H2 2019’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)

– The report reviews pipeline therapeutics for Gouty Arthritis (Gout) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gouty Arthritis (Gout) therapeutics and enlists all their major and minor projects

– The report assesses Gouty Arthritis (Gout) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acquist Therapeutics

Aequus BioPharma Inc

Arthrosi Therapeutics Inc

C&C Research Laboratories

CStone Pharmaceuticals Co Ltd

DevaCell Inc

Dyve Biosciences

Fochon Pharmaceutical Ltd

FortuneRock (China) Ltd

Fuji Yakuhin Co Ltd

Genentech Inc

General Genomics Llc

General Regeneratives Shanghai Ltd

GeneScience Pharmaceuticals Co Ltd

Hinova Pharmaceuticals Inc

Horizon Therapeutics PLC

InflammatoRx inc

InventisBio Inc

Jiangsu Atom Bioscience and Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

LG Chem Ltd

Novartis AG

Olatec Therapeutics LLC

Opsona Therapeutics Ltd

PegBio Co Ltd

Polaris Pharmaceuticals Inc

R Pharm

Rigel Pharmaceuticals Inc

Rubius Therapeutics Inc

Shanghai Pharmaceutical Co Ltd

Shanton Pharma Co Ltd

Swedish Orphan Biovitrum AB

TaiwanJ Pharmaceuticals Co Ltd

Teijin Pharma Ltd

TWi Biotechnology Inc

Veru Inc

Wellstat Therapeutics Corp

XL-protein GmbH”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gouty Arthritis (Gout) - Overview

Gouty Arthritis (Gout) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gouty Arthritis (Gout) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development

C&C Research Laboratories

CymaBay Therapeutics Inc

Genentech Inc

Horizon Pharma Plc

Immune Response BioPharma Inc

Jiangsu Hengrui Medicine Co Ltd

Opsona Therapeutics Ltd

Polaris Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Teijin Pharma Ltd

Wellstat Therapeutics Corp

XL-protein GmbH

Gouty Arthritis (Gout) - Drug Profiles

anakinra - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arhalofenate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-0120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapansutrile - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FYU-981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HZN-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegadricase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REV-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RLBN-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Gout - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Gout - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NLRP3 for Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEI-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URC-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uriSHELS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-2107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gouty Arthritis (Gout) - Dormant Projects

Gouty Arthritis (Gout) - Discontinued Products

Gouty Arthritis (Gout) - Product Development Milestones

Featured News & Press Releases

Apr 10, 2018: Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress

Apr 03, 2018: Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress

Mar 12, 2018: Takeda Announces Results from Uloric (febuxostat) Cardiovascular Outcomes Trial in Patients with Gout and Cardiovascular Disease

Jan 08, 2018: CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America

Nov 15, 2017: Febuxostat: Drug Safety Communication - FDA to Evaluate Increased Risk of Heart-related Death

Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting

Oct 11, 2017: Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

Oct 05, 2017: Selecta Biosciences Announces Upcoming Various Clinical and Scientific Presentations on SEL-212

Jun 15, 2017: Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout

Jun 06, 2017: Selecta Biosciences Announces Upcoming Clinical Presentations

Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

Nov 13, 2016: Results of Study of Febuxostat on the Frequency of Acute Gout Flares in Early Gout

Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Gouty Arthritis (Gout) – Pipeline by Acquist Therapeutics, H2 2019

Gouty Arthritis (Gout) – Pipeline by Aequus BioPharma Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Arthrosi Therapeutics Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by C&C Research Laboratories, H2 2019

Gouty Arthritis (Gout) – Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by DevaCell Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Dyve Biosciences, H2 2019

Gouty Arthritis (Gout) – Pipeline by Fochon Pharmaceutical Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by FortuneRock (China) Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Fuji Yakuhin Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Genentech Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by General Genomics Llc, H2 2019

Gouty Arthritis (Gout) – Pipeline by General Regeneratives Shanghai Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Hinova Pharmaceuticals Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Horizon Therapeutics PLC, H2 2019

Gouty Arthritis (Gout) – Pipeline by InflammatoRx inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by InventisBio Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by LG Chem Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Novartis AG, H2 2019

Gouty Arthritis (Gout) – Pipeline by Olatec Therapeutics LLC, H2 2019

Gouty Arthritis (Gout) – Pipeline by Opsona Therapeutics Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by PegBio Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Polaris Pharmaceuticals Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by R Pharm, H2 2019

Gouty Arthritis (Gout) – Pipeline by Rigel Pharmaceuticals Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Rubius Therapeutics Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Shanton Pharma Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Swedish Orphan Biovitrum AB, H2 2019

Gouty Arthritis (Gout) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by Teijin Pharma Ltd, H2 2019

Gouty Arthritis (Gout) – Pipeline by TWi Biotechnology Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Veru Inc, H2 2019

Gouty Arthritis (Gout) – Pipeline by Wellstat Therapeutics Corp, H2 2019

Gouty Arthritis (Gout) – Pipeline by XL-protein GmbH, H2 2019

Gouty Arthritis (Gout) – Dormant Projects, H2 2019

Gouty Arthritis (Gout) – Dormant Projects, H2 2019 (Contd..1), H2 2019

Gouty Arthritis (Gout) – Dormant Projects, H2 2019 (Contd..2), H2 2019

Gouty Arthritis (Gout) – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports